FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.
What happened
FDA reviewed records the firm submitted after two requests for records under section 704(a)(4) of the FD&C Act, dated September 12, 2022, and February 26, 2024. FDA found significant CGMP violations for finished drugs: inadequate finished-product testing, inadequate stability testing, and no demonstrated testing of incoming isopropyl alcohol for methanol. FDA placed the firm on Import Alert 66-40 on July 3, 2024.
What FDA found
FDA found the firm did not show adequate finished drug product testing, including identity and strength assay and microbiological testing, before release.
21 CFR 211.165(a)FDA found the firm's stability program did not show ongoing chemical and microbiological testing to support the expiry period for products shipped after 2017.
21 CFR 211.166(a)FDA found the firm did not test incoming isopropyl alcohol for methanol and relied solely on the supplier's certificate of analysis for identity testing.
21 CFR 211.84(d)(1) and 211.84(d)(2)
What FDA wants
Respond in writing within 15 working days with what was done to correct violations and prevent recurrence; if not complete, give reasons and a completion schedule. FDA also recommends a qualified CGMP consultant and a six-system audit before resuming U.S. drug manufacturing.
Who should pay attention
- brands and distributors buying OTC drugs from this manufacturer
- importers of Jordan-made rubbing alcohol or OTC drugs
- supplier-quality teams checking alcohol component testing
This is a summary. Read the original letter on fda.gov.